pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
466
stories
8h
Adecto, Aviceda shut down
biospace
9h
STAT+: AstraZeneca opens new Boston site
stat
10h
Shionogi makes $2B rare disease play with IntraBio buy
biospace
11h
KymaThera, Rouge raise VC funding; Vaxcyte, Spyre do public offerings
endpoints
16h
Forbion’s ‘landmark’ €2.3B fundraise to benefit 30 ‘high potential’ biotechs
fiercebiotech
20h
BioSpace 40 Under 40 winners make their mark on biopharma
biospace
20h
TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
fiercebiotech
1d
STAT+: Judges skewer HHS arguments in hearing over Medicare Advantage audits lawsuit
stat
1d
Shionogi to pay $2B for IntraBio, a commercial rare disease biotech
endpoints
1d
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
4d
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
4d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
4d
David Sinclair's latest salvo aims to stall aging with a pill
endpoints
4d
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
5d
3 takeaways from a European obesity scientific meeting
biopharma dive
5d
Foghorn lays off 40% of staff after Lilly collaboration ends
biospace
5d
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
fiercebiotech
6d
FDA starts review of Roche’s multiple sclerosis pill
biopharma dive
6d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
7d
Webinar: From Facility to Delivery: Solving the Complex Science of ADC Linker-Payload Synthesis
biospace
7d
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
7d
Ascletis challenges psoriasis field with pill; Invivyd plans Covid filing
endpoints
7d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
7d
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
stat
7d
Enanta sheds staffers as key antiviral, immunology readouts loom
fiercebiotech
7d
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
7d
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
fiercebiotech
7d
Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug
endpoints
7d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
8d
FDA Approves First Treatment for MCT8 Deficiency
fda press
← prev
page 1 of 16
next →
